MarketCapExport financials
R1 RCM (RCM)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
R1 RCM Balance Sheet 2021-2008 | RCM
Brief overview of R1 RCM 's assets and capital
The comparison uses five available annual reports from the 2017–2021 interval.
The asset base grew from $336 million to $1.4 billion, or +331.3%. Average annual growth of roughly 44.1% was strong.
Liabilities grew faster than assets: +873.2% versus +331.3%. A substantial part of expansion was externally funded.
Internal capital represents 23.9% of the balance sheet versus 9.9% five periods ago. The cushion is thin.
Each unit of equity supports 1.84x of net debt. This elevated load requires dependable cash generation.
Cash accounts for 9% of assets versus 49.1% initially. The change indicates the degree of financial flexibility.
Retained earnings remain negative at -$64.3 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
What the balance sheet shows
R1 RCM 's financial structure calls for caution. Stronger equity, lower debt or restored liquidity would be needed to improve it.
Annual Balance Sheet R1 RCM
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
638 M | 358 M | 258 M | 296 M | - | -181 M | -103 M | -145 M | -229 M | -177 M | -197 M | - | - | - |
Long Term Debt |
755 M | 520 M | 338 M | 356 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
13.5 M | 12.2 M | 12.8 M | 2.7 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 895 M | 449 M | 397 M | 23.4 M | 121 M | 441 M | 325 M | 203 M | 85.8 M | 11.2 M | 3.91 M | - | - |
Total Current Liabilities |
254 M | 206 M | 232 M | 196 M | 89.9 M | 135 M | 233 M | 263 M | 393 M | 708 M | 513 M | 116 M | - | - |
Total Liabilities |
1.1 B | 850 M | 682 M | 593 M | 113 M | 256 M | 674 M | 589 M | 596 M | 794 M | 578 M | 120 M | - | - |
Deferred Revenue |
- | - | 14 M | 14.7 M | 4 M | 83.9 M | 132 M | 152 M | 256 M | 605 M | 24.1 M | 21.9 M | - | - |
Retained Earnings |
-64.3 M | -162 M | -278 M | -290 M | -244 M | -305 M | -482 M | -398 M | -318 M | -448 M | -328 M | -256 M | - | - |
Total Assets |
1.45 B | 1.19 B | 929 M | 808 M | 336 M | 415 M | 460 M | 446 M | 510 M | 557 M | 476 M | 263 M | - | - |
Cash and Cash Equivalents |
130 M | 174 M | 92 M | 62.8 M | 165 M | 181 M | 104 M | 145 M | 229 M | 177 M | 197 M | 156 M | 43.7 M | 51.7 M |
Book Value |
347 M | 339 M | 247 M | 215 M | 223 M | 159 M | -213 M | -142 M | -85.6 M | -236 M | -101 M | 143 M | - | - |
Total Shareholders Equity |
347 M | 87.9 M | 18.1 M | 6.3 M | 33.4 M | -12.3 M | -213 M | -142 M | -85.6 M | -236 M | -101 M | -95.8 M | 21.3 M | 7.92 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet R1 RCM
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 751 M | 755 M | 779 M | 501 M | 510 M | 520 M | 529 M | 539 M | 363 M | 338 M | 352 M | 366 M | 356 M | 356 M | 356 M | 357 M | 356 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.2 M | 14 M | 13.4 M | 11.2 M | 4 M | 3.94 M | 11.2 M |
Total Liabilities |
- | - | - | 1.07 B | 1.1 B | 1.15 B | 856 M | 851 M | 850 M | 896 M | 855 M | 677 M | 682 M | 663 M | 690 M | 691 M | 593 M | 554 M | 531 M | 126 M | 113 M | 94.8 M | 80.8 M | 83.6 M | 256 M | 308 M | 387 M | 388 M | 674 M | 714 M | 654 M | 617 M | 589 M | 616 M | 604 M | 639 M | 596 M | 596 M | 596 M | 596 M | 794 M | 171 M | 162 M | 153 M | 578 M | 139 M | 121 M | 126 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | 18.8 M | 19.9 M | 13.3 M | 14 M | 10.9 M | 13.2 M | 11.2 M | 14.7 M | 12.5 M | 8.5 M | 3.8 M | 4 M | 3.1 M | 1.7 M | 1.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.3 M | 21.4 M | 31.9 M | 24.1 M | 19.2 M | 19.3 M | 24.1 M |
Retained Earnings |
- | - | - | -34.9 M | -64.3 M | -100 M | -117 M | -136 M | -162 M | -240 M | -245 M | -260 M | -278 M | -286 M | -295 M | -290 M | -290 M | -284 M | -271 M | -268 M | -244 M | -204 M | -201 M | -194 M | -305 M | -318 M | -355 M | -314 M | -482 M | -487 M | -454 M | -428 M | -398 M | -380 M | -389 M | -373 M | -318 M | -318 M | -318 M | -318 M | -448 M | 15 M | 12.2 M | 12.8 M | -328 M | -1.85 M | -9.12 M | 11.3 M |
Total Assets |
- | - | - | 1.44 B | 1.45 B | 1.48 B | 1.18 B | 1.13 B | 1.19 B | 1.2 B | 1.14 B | 943 M | 929 M | 901 M | 913 M | 908 M | 808 M | 768 M | 753 M | 345 M | 336 M | 354 M | 342 M | 351 M | 415 M | 450 M | 493 M | 526 M | 460 M | 491 M | 464 M | 447 M | 446 M | 489 M | 463 M | 508 M | 510 M | 510 M | 510 M | 510 M | 557 M | 429 M | 423 M | 408 M | 476 M | 348 M | 313 M | 364 M |
Cash and Cash Equivalents |
- | - | - | 124 M | 130 M | 159 M | 165 M | 104 M | 174 M | 106 M | 123 M | 106 M | 92 M | 55.6 M | 80.1 M | 117 M | 62.8 M | 52.4 M | 38.8 M | 168 M | 165 M | 143 M | 132 M | 143 M | 181 M | 202 M | 222 M | 281 M | 104 M | 138 M | 122 M | 132 M | 145 M | 194 M | 154 M | 208 M | 229 M | 229 M | 229 M | 229 M | 177 M | 196 M | 201 M | 214 M | 197 M | 182 M | 150 M | 197 M |
Book Value |
- | - | - | 366 M | 347 M | 334 M | 322 M | 284 M | 339 M | 308 M | 286 M | 266 M | 247 M | 239 M | 223 M | 217 M | 215 M | 214 M | 222 M | 219 M | 223 M | 260 M | 261 M | 267 M | 159 M | 142 M | 106 M | 138 M | -213 M | -224 M | -190 M | -170 M | -142 M | -127 M | -141 M | -130 M | -85.6 M | -85.6 M | -85.6 M | -85.6 M | -236 M | 258 M | 261 M | 255 M | -101 M | 208 M | 192 M | 238 M |
Total Shareholders Equity |
- | - | - | 366 M | 347 M | 334 M | 322 M | 284 M | 87.9 M | 62.5 M | 46.1 M | 31.5 M | 18.1 M | 14.8 M | 4.4 M | 3.8 M | 6.3 M | 10 M | 23.7 M | 25.1 M | 33.4 M | 74.9 M | 80.7 M | 91.3 M | -12.3 M | -24.9 M | -57.5 M | -21.4 M | -213 M | -224 M | -190 M | -170 M | -142 M | -127 M | -141 M | -130 M | -85.6 M | -85.6 M | -85.6 M | -85.6 M | -236 M | 258 M | 261 M | 255 M | -101 M | 208 M | 192 M | 238 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of R1 RCM , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
American Well Corporation
AMWL
|
$ 13.97 | 5.91 % | $ 224 M |  USA |
 |
Evolent Health
EVH
|
$ 4.83 | -0.82 % | $ 552 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Omnicell
OMCL
|
$ 36.34 | -0.41 % | $ 1.67 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.37 | 4.93 % | $ 174 M | USA |
 |
Phreesia
PHR
|
$ 12.26 | 1.78 % | $ 732 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.57 | 1.42 % | $ 1.27 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.74 | -0.57 % | $ 122 M | USA |
 |
So-Young International
SY
|
$ 2.19 | -3.1 % | $ 171 M |  China |
 |
Teladoc Health
TDOC
|
$ 6.3 | 1.45 % | $ 1.11 B | USA |
 |
HealthEquity
HQY
|
$ 97.88 | 1.33 % | $ 8.43 B | USA |
 |
Veeva Systems
VEEV
|
$ 320.55 | 0.59 % | $ 52.5 B | USA |
 |
Schrödinger
SDGR
|
$ 23.9 | 2.14 % | $ 1.76 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.34 | -4.96 % | $ 4.58 M | China |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
HealthStream
HSTM
|
$ 33.51 | -0.77 % | $ 1.01 B | USA |
 |
Progyny
PGNY
|
$ 28.44 | -0.49 % | $ 2.42 B | USA |
 |
10x Genomics
TXG
|
$ 75.59 | 5.78 % | $ 9.43 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |